| Literature DB >> 3338052 |
L S Lashford1, A G Davies, R B Richardson, S P Bourne, J A Bullimore, H Eckert, J T Kemshead, H B Coakham.
Abstract
A pilot study was performed to investigate the toxicity and therapeutic effect of radiolabeled antibody administered intrathecally in patients with leptomeningeal tumors. Five patients who failed conventional therapy received between 11 mCi and 40 mCi of radiolabeled antibody. The choice of antibody varied depending on the immunophenotype of the tumor. Therapy was well tolerated generally, with minimal acute toxicity. Four of five patients achieved an objective response to treatment that has been sustained for a period varying from 7 months to 2 years. No clinical signs of chronic toxicity have been observed in patients 1 and 2 years after therapy.Entities:
Mesh：
Substances：
Year: 1988 PMID： 3338052 DOI： 10.1002/1097-0142(19880301)61:5<857::aid-cncr2820610502>3.0.co;2-s
Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.860